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Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin
intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose
level for phase II trials. This was an open-labelled, nonrandomised dose-escalation phase I study. In all, 12 patients with a history of
recurrent superficial bladder cancer were grouped into four dose levels (10–150mgml
 1 in 60ml saline). Six catheter instillations at
weekly intervals were used. Cystoscopy and biopsy were performed before and 3 months after the start of treatment. Suramin was
assayed using high-performance liquid chromatography, vascular endothelial growth factor (VEGF) using ELISA (enzyme-linked
immunosorbent assay), and urinary protein profile using surface-enhanced laser desorption ionisation mass spectroscopy (SELDI).
Minimal systemic absorption of Suramin was found at the highest dose of 150mgml
 1. Urinary VEGF was affected by Suramin at
doses above 50mgml
 1, corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. SELDI showed
a specific disappearance of urinary protein peaks during treatment. Intravesical Suramin shows lack of toxicity and low systemic
absorption. The results of this phase I trial support expanded clinical trials of efficacy at a dose of 100mgml
 1 intravesically.
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Bladder cancer has an incidence of 30/100000 per year and three-
quarters of patients present with superficial disease. In all, 30% of
intermediate-risk superficial bladder tumours will recur within 2
years despite intravesical treatment with mitomycin C, and around
6% may progress to cause death within a median follow-up of
7 years (Tolley et al, 1996). The incidence of recurrence can be
reduced with current intravesical regimens, with agents such as
mitomycin C, epirubicin, or Bacillus Calmette Guerin (BCG). The
drawback to current intravesical therapies is their toxicity and
resistance to their effects.
Suramin is a polysulphonated naphthylurea and a potent
antagonist of vascular endothelial growth factor (VEGF) (Bikfalvi
et al, 1991). Suramin inhibits in vitro activity of several angiogenic
factors produced by bladder cancer cell lines (Gansler et al, 1992;
Walther et al, 1994) and cell proliferation. Suramin also inhibits
basic fibroblast growth factor-induced angiogenesis in vivo in mice
(Hosang, 1985; Coffey et al, 1987; Huang and Huang, 1988; Kopp
and Pfeiffer, 1990; Fuller-Pace et al, 1991; Pesenti et al, 1992;
Waltenberger et al, 1996), the activity of heparanase (Marchetti
et al, 2003), and urokinase-type plasminogen activator (Marutsuka
et al, 1995). We previously showed inhibition of the invasion of
bladder cancer cell lines with Suramin in a bladder tissue explant
model (Fujiyama et al, 2001).
VEGF is a rational target in superficial bladder cancer. We
previously have shown that high VEGF levels in primary super-
ficial tumours or in urine are related to early relapse and stage
progression (O’Brien et al, 1995; Crew et al, 1996, 1997, 1999), and
normal bladder, adjacent to the tumour, has VEGF levels much
higher than nonmalignant controls. Since many recurrences are
genetically identical to the primary, seeding is a possibility
(Duggan et al, 2004) and prevention of vascularisation of each
lesion may prevent recurrence and invasion.
When administered systemically, a wide range of serious side
effects have been reported for Suramin including haematologic,
ocular, metabolic (adrenal insufficiency; La Rocca et al, 1990),
renal (acute failure; Figg et al, 1994) and neurological (Bowden
et al, 1996). Suramin has a lengthy plasma half-life of approxi-
mately 40 days in man (Hawking, 1978), and renal clearance
accounts for almost all the drug’s elimination. There are a number
of inherent advantages to the administration of Suramin
intravesically. Owing to its relatively high molecular mass (1429
vs 334 for mitomycin C), systemic absorption should be very low.
Additionally, in the plasma, 99.7% of Suramin is protein bound,
which may interfere with its availability to bind growth factors.
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bioavailability. Graham reported excellent efficacy when given
intravesically to rats in a chemically induced model of bladder
cancer (Graham et al, 1995).
This study describes a phase I and pharmacological study of
Suramin given intravesically to patients with bladder cancer. The
primary objective of the study was to establish a recommended
dose level of intravesical Suramin based on toxicity profile and
pharmacodynamic end point of VEGF binding. The secondary
objective was to investigate the effect of Suramin on bladder
biopsies assessed by immunohistochemistry and to monitor global
changes in urinary proteins using surface-enhanced laser deso-
rption ionisation mass spectroscopy (SELDI).
PATIENTS AND METHODS
Eligibility
Patients for whom a rigid cystoscopy had been indicated following
previous treatment for superficial bladder cancer or who had
symptoms indicating a possible recurrence were included.
Recurrences were detected using flexible cystoscopy. Entry criteria
were that patients had to be 18 years or older, have a World Health
Organization (WHO) performance status of 0–2, and have no toxic
manifestations of previous treatments. Inclusion criteria were
presence of Ta, T1, and Grade 1 or 2 multiple tumours (but not
47). Patients with single or 47 tumours, stage T2 4b, Grade 3 or
carcinoma in situ (from four random bladder biopsies taken at
pretreatment cystoscopy) were excluded. Concurrent treatment
for other malignancies, prior radiotherapy, anticoagulant therapy,
a history of adrenal insufficiency or steroid therapy were also
exclusion criteria, as well as clinically significant hepatic or renal
disease.
Dose and dose escalation
Suramin was supplied by the NCI (USA), Division of Cancer
Treatment and Diagnosis, in lyophilised form as a powder stored
at room temperature. Suramin is freely soluble in water. The dose
was diluted in 60ml normal saline for each intravesical instillation.
Patients were grouped into four treatment levels, with intergroup
dose escalation as the trial progressed. Significant, that is, Grade 3
(NCI Common Toxicity Criteria), toxicity would prevent progres-
sion to the next treatment level and expand recruitment to a
maximum of six patients at that level. Dose levels are described in
Table 1.
Study design
The protocol was approved by the CRC (Cancer Research
Campaign) Protocol Review Committee, the CIRB (Central
Institutional Review Board), and the Local Research Ethics
Committee (LREC). The study was carried out in accordance with
the Declaration of Helsinki. Written informed consent was
obtained. This was an open-labelled, nonrandomised phase I
study with an intended recruitment of 12 patients. Pretreatment
evaluation included full history, physical examination, and
assessment of WHO performance status. In addition, a complete
blood count, clotting screen, renal, and liver biochemical profiles
and urine analysis were performed. These were repeated weekly
and 3 weeks after the end of treatment. At the pretreatment
transurethral resection of bladder tumour (TURBT), random
biopsies of normal bladder and samples of the tumour were taken,
and both were fixed in formalin and paraffin embedded.
Patients received their first instillation of Suramin at least 14
days postcystoscopy and TURBT. This was to allow the bladder to
heal and to reduce systemic absorption. The drug was then given
once a week for 6 weeks. The bladder was drained prior to and
postinstillation. Treatments were left in situ for 2h, during which
time the patient remained horizontal, and was asked to turn
through 901 every 15min.
At 3 weeks after the end of the treatment, a further cystoscopy
was performed under general anaesthetic and further random
biopsies taken with tumour resection if necessary.
Sample handling
Blood samples were collected in EDTA tubes and centrifuged at
2000g for 10min within 30min of sampling. The plasma was
stored in aliquots at  701C. The volume of urine drained from the
bladder at the end of 2h was measured. An aliquot of 10ml of
urine was collected, 1ml of protease inhibitor was added (Sigma
P2714, Protease Inhibitor Cocktail containing AEBSF, bestatin,
EDTA, E-64, leupeptin, and aprotinin), and the urine was
centrifuged at 2000g for 10min within 30min of sampling.
Aliquots were stored at  701C. It has previously been shown that
protease inhibitor does not affect VEGF results (Crew et al, 1999).
Suramin pharmacokinetics
Suramin concentration in plasma and urine was determined using
a high-performance liquid chromatography (HPLC) assay follow-
ing protein precipitation. Briefly, 200mlo f1 M tetrabutyl ammo-
nium bromide (ion-pairing agent) and 200ml1 0 mgml
 1
methylphenyl-phenyl-hydantoin (internal standard) were added
to a 250ml sample (plasma or urine). Proteins were then
precipitated with 500ml methanol by incubation at 41C for
30min, after which the supernatant was injected into the HPLC
system. Standard curves covered the range of 0–30mgml
 1 plasma
and 0–200mgml
 1 urine. Urine samples were diluted by up to 900-
fold (depending on the dose level) with water to ensure the
concentration was within the standard range. Separation of peaks
of interest was achieved using a 5mM Hypersil C18 column (Jones
Chromatography, Hengoed, Wales) and a mobile phase compri-
sing 10mM phosphate buffer (10mM disodium hydrogen phos-
phate and 10mM sodium dihydrogen phosphate, pH 7.5), with
4m M tetrabutylammonium bromide and 52.5% methanol. Eluting
peaks were monitored at 230nM by UV detection. The limit of
quantitation was 0.5mgml
 1 plasma and 5mgml
 1 urine. Repro-
ducibility (covariance) of quality control samples at 0.5, 4, and
20mgml
 1 plasma and 5 and 50mgml
 1 urine was o12%. This
protocol released Suramin from protein and measured total
Suramin.
Pharmacodynamics
VEGF was measured in the urine and plasma using a standard
enzyme-linked immunosorbent assay (ELISA) (R&D Systems)
before each Suramin dose and was compared with that detectable
after each Suramin dose. This ELISA has previously been tested for
use with urinary samples for recovery of VEGF from urine (Crew
et al, 1999). Minimum detectable dose of VEGF by this ELISA is
typically less than 5pgml
 1.
To assess the general effect of Suramin instillation on global
urine protein profiles, urine samples were also analysed using
Table 1 Suramin dose levels vs treatment group
Dose level Concentration of Suramin (mgml
 1) Total dose (mg)
1 10 600
2 50 3000
3 100 6000
4 150 9000
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instrument was calibrated at the start and end of the run using
bovine ubiquitin (MW 8564.8), bovine superoxide dismutase (MW
15591.4), and bovine b-lactaglobulin A (MW 18363.34). Samples
were loaded using a bioprocessor as described previously (Rogers
et al, 2003), but for SAX chips, the buffer used for binding,
dilution, and washing was 20mM sodium phosphate, pH 8.0/0.1%
(vv
 1) NP40 and for the H4 chips it was prewet with 50%
acetonitrile with 10% acetonitrile/0.1% TFA being used for wash
steps. Additionally, in each case, sample loading was standardised
on the basis of creatinine with a diluted volume of urine equivalent
to a final creatinine concentration of 2.5mM being loaded in a
50ml volume. Samples were analysed using parameters of a high
mass of 100kDa, optimum mass range 3–20kDa, laser intensity of
210, sensitivity of 10 and collecting 50 transients across the spot
surface. This was carried out on samples pre- and post-Suramin
dose 1, pre- and postdose 5 or 6, and on the 4 weeks post-
treatment samples for each of three patients (patient 7 at dose level
2 and two patients 9 and 12 at dose level 3). Samples were all
analysed on the same batch of chips on a single day to minimise
variability.
Immunohistochemistry
Paraffin sections of paired normal bladder available from 11
patients were heated to 601C for 15min, dewaxed in citrate, and
rehydrated by passage through graded alcohols. Sections of normal
bladder were stained for VEGF bound to KDR (VEGFR2) receptor
using 11B5 monoclonal antibody (East Coast Biologics Inc., North
Berwick, ME, USA). (Brekken et al, 1998). Antigen retrieval was
carried out by pressure-cooking for 3min in 0.01 M citrate, pH 6.0.
Primary antibody was applied (1:4 in 1 TBS) for 1h. Control
slide used was normal human tonsil where staining of vessels,
stromal cells and luminal surface was seen. Labelling was detected
using anti-mouse system (Dako) as per the manufacturer’s
instructions. Sections were then counterstained with haematoxylin
and mounted. Staining of blood vessels was performed with anti-
CD34 (QBEnd 10 antibody) at a final concentration of 1:100 using
a similar protocol. The number of CD34-stained microvessels was
counted in the lamina propria immediately adjacent to the
urothelium on a high-power ( 40 objective) lens and the
proportional vascular space volume determined using a Chalkley
point graticule (Chalkley, 1943). Between 5 and 10 adjacent high-
power fields were counted for each specimen. The highest three
values were taken as hotspots and the mean was taken.
RESULTS
In all, 12 patients were entered into the study, all of whom were
evaluable for toxicity. Their details are shown in Table 2.
Toxicity
Three patients experienced minor rises in fasting blood glucose
(insufficient for a diagnosis of diabetes mellitus) and one patient
developed minor lymphopenia at the lowest dose level, of
unproven significance. No serious adverse events were noted and
no patients complained of urinary symptoms related to treatment.
In fact, two patients previously with nocturnal frequency of
micturition noted a marked improvement in this symptom while
receiving treatment. There were no drug-related adverse events
above Grade 1.
Clinical outcome
Three patients had recurrent tumours and two had dysplasia at the
final cystoscopy. Four of these were in the lower two dose groups
(4/6 vs 1/6 Fisher’s exact test not significant P¼0.2).
Urine pharmacokinetics
All urine samples immediately before preinstillation had unde-
tectable levels of Suramin. Urine drained at the termination of each
instillation contained levels as shown in Figure 1. There was a clear
relationship between urinary Suramin concentration and dose with
mean levels of 28.7 and 42.0mgml
 1 at the two highest levels.
Repeat analysis of urine samples from four patients for internal
consistency showed that in all cases the final results were within
5% of one another. From this evidence, dilutional or assay error
accounts for o5% deviation between results. The calculated total
amount of Suramin recovered at the end of the instillation for four
complete treatment courses was 87% (s.d. 28%).
Table 2 Details of the patients entered into the Suramin trial, also showing histology of recurrences
Patient number Dose level Dose level (mgml
 1) Number of instillations Age (years) Gender Histology Recurrence post-treatment
1 1 10 6 71 Female G2/T1 G2/T1
2 1 10 6 61 Male G2/Ta
3 1 10 6 61 Male G2/T1 Dysplasia
4 2 50 6 65 Male G1/Ta
5 2 50 6 57 Male G2/Ta G2/Ta
6 2 50 6 81 Male G2/Ta Dysplasia
7 3 100 6 64 Male G2/Ta
8 3 100 6 52 Female G1/Ta
9 3 100 6 59 Male G1/Ta
10 4 150 6 69 Male G2/Ta
11 4 150 6 63 Female G1/Ta G1/Ta
12 4 150 6 62 Male G1/Ta
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Figure 1 Mean postdose urinary Suramin concentrations by dose level
(see Table 1). This represents the concentration of urine drained from the
bladder at the end of the 2-h instillation. Error bar equals 1s.d. Differences
between groups are highly significant (two-tailed t-test, variances not
assumed to be equal Po0.01).
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In all, 12 patients were evaluable for pharmacokinetics. All plasma
samples for patients up to and including level 3 had no detectable
Suramin, that is, less than 0.5–6mgml
 1. Two patients at dose
level 4 had detectable Suramin levels above 6mgml
 1. These were
in patient 11 after instillations 5 and 6 with levels of 6.3mgml
 1,
1163mgml
 1, respectively, and in patient 12 after instillation 5 with
a level of 333mgml
 1. High levels were diluted and rerun, with the
repeat confirming the value in both cases. No clinically traumatic
catheterisation occurred during the study. These patients were not
receiving any different drugs on these days compared to other
days.
Pharmacodynamics: plasma and urine VEGF
Suramin shows high affinity for the heparin-binding growth factor
VEGF. Standard samples of VEGF were spiked with increasing
concentrations of Suramin, with resulting interference of the VEGF
ELISA as shown by the poor recoveries in Figure 2. The ELISA is
inhibited by only small concentrations of Suramin, for example,
2mgml
 1 causing an approximate 40% fall in the measured level
of VEGF at all concentrations, while 150mgml
 1 caused almost a
100% fall at all concentrations compared with control. A number
of means were tried to disrupt the interaction between Suramin
and VEGF. These included dialysis through a semipermeable
membrane, passage through an ion-exchange column (Suramin
having a negative charge), dissolution in 4 M NaCl, and the
addition of 10% SDS followed by boiling. None of these methods
had any effect on the VEGF–Suramin binding as measured by
ELISA (data not shown). A similar effect was demonstrated using
spiked human urine samples; thus, in the data that follows, VEGF
levels must be interpreted in the light of measured Suramin
concentrations and reflect free VEGF concentrations.
In all, 12 patients were evaluable for pharmacodynamics. Plasma
VEGF results did not change significantly over the course of
treatment at any dose level. Plasma levels of VEGF were in the
normal range for all patients, except patient number seven, who
for unknown reasons had persistently raised levels.
Urinary VEGF was quantified by ELISA with values normalised
to urinary creatinine, to adjust for variation in urine concentration
(Figure 3A). Mean VEGF levels immediately before each treatment
and at the end of the treatment course are shown by dose cohort
(Figure 3B). The measurement of urinary VEGF levels was
profoundly affected by the presence of Suramin, especially at
doses above level one. This corresponds to the previously
demonstrated inhibition of the VEGF ELISA by concentrations of
Suramin as low as 2mgml
 1. Suramin did not alter urinary VEGF
over the course of treatment on average, as assessed by the baseline
value before each instillation.
Surface-enhanced laser desorption/ionisation
Although the convention with urine samples is to normalise results
for urine creatinine to correct for hydration status, differences in
protein loading on SELDI chips can influence the profile (Rogers
et al, 2003). For comparison of profiles, samples ideally should
be loaded normalised for protein, therefore (Rogers et al, 2003).
However, in this study, it proved impossible to assay protein
concentration due to the interference of Suramin. Therefore,
loading was normalised by creatinine, which should allow
intrapatient comparison. Generally, the profiles on both the
CM10 and H4 chips post-Suramin treatment showed a marked
loss or reduction of peak number (Figure 4). However, it was
noticeable that not all peaks were affected to the same extent with
the peak at 9732.7–9741.2 with both the SAX2 and H4 chips being
little affected. Conversely, in patients 9 and 12, the appearance of
peaks at 4746.0–4749.2 and 5063.8–5069.2 on the SAX2 chips was
noted with Suramin treatment. Although not examined under
optimal higher laser intensities, similar loss of peaks was also seen
in the higher mass region, although far fewer peaks are seen there.
The profiles generated 4 weeks postcessation of treatment
resembled the pretrial profiles.
Immunohistochemistry
In all, 22 normal bladder biopsies from 11 patients pre- and post-
treatment were available for staining. Mean microvessel count
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Figure 2 Suramin interference with VEGF ELISA. Standard concentrations of VEGF were spiked with different levels of Suramin, and then the VEGF was
measured.
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 3 (s.d. 45) and in post-
treatment 140mm
 3 (s.d. 56), and mean proportional vascular
volume estimated using the Chalkley random point graticule was
17% (s.d. 5.2) and 18% (s.d. 3.0), respectively (NS paired t-test).
Mean microvessel count in severely inflamed samples (n¼4,
mean 186mm
 3, s.d. 66) was significantly higher (P¼0.04) than in
mildly or noninflamed samples (n¼18, mean 131mm
 3, s.d. 42)
and there was a trend to higher proportional vascular volume
in severely inflamed samples (mean 23%, s.d. 5.2% vs mean 16%,
s.d. 2.9%, P¼0.07). The number of inflamed samples in pre- and
post-treatment groups was not significantly different: two severely
inflamed samples in each group, overall seven biopsies reported as
any degree of inflammation in pretreatment group, and nine
inflamed in post-treatment. Figure 5 illustrates typical staining
patterns seen in the inflamed and the noninflamed bladder.
VEGF staining was scored on the basis of intensity and breadth
of staining of the urothelium. Positive was defined as a biopsy
showing full thickness epithelial staining either in patches or along
the entire epithelial border. All biopsies showed staining of the
umbrella layer of the urothelium, but there was no significant
difference between pre- and postbiopsy samples in full thickness
staining: four of 11 pretreatment biopsies stained positive and two
of 11 post-treatment stained positive. Three of nine noninflamed
and three of 13 inflamed were positive. Neither difference was
significant (w
2 test).
DISCUSSION
This trial has shown low toxicity, and the low systemic absorption
of Suramin occurred only at the highest dose. Dose determination
principally rests on the interpretation of pharmacodynamic data
concerning the efficacy of Suramin in inhibiting the action of
heparin-binding growth factors as surrogate markers of activity.
Suramin greatly interfered with the ELISA quantification of
VEGF in urine. This inhibition of protein–protein interaction on
which the ELISA depends is likely to be due to free Suramin
binding VEGF and preventing antibody attachment to its antigen.
Binding of Suramin to albumin, the main protein in the urine, will
be dependent on their relative concentration ratio, as determined
previously (Roboz et al, 1998). When Suramin is in excess of
albumin, as in the vast majority of cases here, the number of
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Figure 3 (A) Urine VEGF pre- and postdose by individual patient. Individual patients are indicated by a number from 1 to12. (B) Urine VEGF pre- and
postdose grouped by dose level of Suramin. Three patients per level; difference between level 1 and other levels Pp0.05 is seen at postdoses 1, 2, 3 and 5.
Error bars equal s.e.m.
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maximum of 20 Suramin per albumin. Assuming albumin
concentrations in urine up to a normal range of 20mgl
 1,u pt o
10mgml
 1 Suramin may be bound. Once this threshold is
exceeded, inhibition of urinary VEGF quantification by ELISA
occurs. This end point was considered a desirable biological effect
to assess the ability of the free Suramin to inhibit a high-affinity
specific interaction of VEGF with a binding site.
This was found in all cases at dose level 2 (50mgml
 1 Suramin
instilled), Figure 3B. The mean postdose urinary Suramin
concentration measured at this level was 18mgml
 1 (Figure 1).
The one patient in whom VEGF quantification was not completely
inhibited at this level was the one who produced the most urine
during the 2-h instillation period; mean Suramin concentration
was 11mgml
 1. Full inhibition of the VEGF ELISA was only
attained in patients treated with level 3 dosing (100mgml
 1
Suramin instilled) in whom mean postdose urinary Suramin
concentration was 29mgml
 1. Of particular note, this is 300 times
higher than the concentration required to inhibit transitional cell
carcinoma cell growth in culture (Gansler et al, 1992).
One other phase I trial of intravesical Suramin has been
published (without pharmacodynamic data) with the majority of
the nine patients receiving between 0.3 and 154mgml
 1 dose in
60ml of normal saline over a 6-week period (Uchio et al, 2003).
Bladder spasms associated with treatment occurred only in two
patients with concentrations over 300mgml
 1. Systemic absorp-
tion was o40mgml
 1 in all patients.
In our study, two treatments at the highest dose level of
150mgml
 1 demonstrated high systemic absorption (334 and
1163mgml
 1 plasma level postdose). There was no associated
clinical adverse effect. Plasma levels above 275mgml
 1 when
maintained for over 4 weeks by intravenous infusion cause
clinically significant neurological adverse effects such as paresis
(Bowden et al, 1996). With a long half-life of 40 days, toxicity from
a one-off level of 334mgml
 1 could potentially be significant.
Plasma Suramin returned to o1mgml
 1 1 and 3 weeks
Predose 1
Predose 6
Postdose 1
Postdose 6
4–6 Weeks post-
treatment
5000 10 000 5000 10 000
m/z
AB
Figure 4 SELDI profiles of urine samples from patient 9 on a SAX2 chip (A) and patient 12 on an H4 chip (B). Pre- and postdose 1 and 6, and 4 weeks
postcessation of Suramin treatment. Arrows identify peaks that are either lost or gained.
Normal bladder  Inflamed bladder  
Figure 5 Staining for blood vessels in inflamed and noninflamed bladder with antibodies to CD31.
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these represent transient peaks and do not produce a reservoir.
SELDI provides a semiquantitative means of profiling, although
many factors may affect the results including ion suppression. The
general trend was of less protein peaks in the urine samples post-
Suramin, although not all proteins were affected to the same
extent. This was also seen if Suramin was spiked into urines in
vitro and therefore is unlikely to reflect effects of Suramin on
release of protein by bladder cells. Suramin, which is negatively
charged, may compete with proteins binding to the chip surface
with selective effects due to relative binding affinities. Alterna-
tively, binding of Suramin to specific proteins may either alter
their binding properties or cause their aggregation.
Three patients had recurrent tumours and two had dysplasia at
the final cystoscopy. Four of these five recurrences were in the
lower two dose groups. These numbers are insufficient to reach
statistical significance, but the trend to fewer recurrences in
the higher dose groups supports the laboratory end point
determination.
In conclusion, intravesical Suramin is well tolerated in the
treatment of patients with recurrent superficial bladder cancer.
Levels are undetectable in the blood until the intravesical dose
reaches 150mgml
 1. Inhibition of the VEGF ELISA occurred
reliably in patients at the 100mgml
 1 level but not at lower levels.
These results support the progression to expanded clinical trials of
efficacy using a dose of 100mgml
 1 intravesically.
Our in vitro bladder explant model (Fujiyama et al, 2001)
suggested that Suramin very effectively inhibits implantation;
therefore, the most effective time for Suramin administration may
be at the time of resection as demonstrated with mitomycin C
(Tolley et al, 1996). In our study, the first instillation was 14–18
days postresection to allow the bladder to heal and reduce systemic
absorption. However, the low toxicity demonstrated and the
recovery of urine VEGF levels after 1 week suggest that one or
more doses of Suramin could be given at the time of resection and
within the first 2 weeks. Theoretically, the healing bladder wound
might secrete high levels of VEGF or heparin-binding growth
factors encouraging tumour cell survival. Suramin’s effect on
superficial tumour itself was not assessed in this study; a study
utilising a marker lesion would be better placed to do that.
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